Hyperforin induces apoptosis of chronic lymphocytic leukemia cells through upregulation of the BH3-only protein Noxa

International Journal of Oncology

Volumn 40, Issue 1, 2012, Pages 269-276

  Zaher, Murhaf ^a,b,c   Tang, Ruoping ^a,b,c   Bombarda, Isabelle ^d   Merhi, Faten ^a,b,c   Bauvois, Brigitte ^a,b,c   Billard, Christian ^a,b,c  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d CNRS   (France)

Author keywords

Apoptosis induction; CLL; Hyperforin; Mcl 1 Bak interaction; Noxa upregulation

Indexed keywords

ACTIN; BH3 PROTEIN; CASPASE; HYPERFORIN; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEASOME; PROTEIN BAK; PROTEIN BCL 2; PROTEIN MCL 1; PROTEIN NOXA; SMALL INTERFERING RNA;

ADULT; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CHRONIC LYMPHATIC LEUKEMIA; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISSOCIATION; DRUG MECHANISM; ENZYME INHIBITION; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; HYPERICUM PERFORATUM; MALE; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; TRANSLATION REGULATION; UPREGULATION;

AGED; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; FEMALE; GENE SILENCING; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PHLOROGLUCINOL; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, SMALL INTERFERING; TERPENES; TRANSFECTION; UP-REGULATION;

EID: 84455193932     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1206     Document Type: Article

References (45)

1. Tam CS and Keating MJ: Chemoimmunotherapy of chronic lymphocytic leukemia. Nat Rev Clin Oncol 7: 521-532, 2010.
2. Dighiero G and Hamblin DJ: Chronic lymphocytic leukemia. Lancet 371: 1017-1029, 2008.
3. P leyer L, Egle A, Hartmann TN and Greil R: Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nat Rev Clin Oncol 6: 405-418, 2009.
4. Kolb JP, Kern C, Quiney C, Roman V and Billard C: Re-establishment of a normal apoptotic process as a therapeutic approach in B-CLL. Curr Drug Targets Cardiovasc Hematol Disord 3: 261-286, 2003. (Pubitemid 37540859)
5. Adams JM and Cory S: The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26: 1324-1337, 2007. (Pubitemid 46328466)
6. Kitada S, Andersen J, Akar S, et al.: Expression of apoptosisregulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 91: 3379-3389, 1998. (Pubitemid 28193890)
7. Gandhi V, Balakrishnan K and Chen LS: Mcl-1: the 1 in CLL. Blood 112: 3538-3540, 2008.
8. Pepper C, Lin TT, Pratt G, et al.: Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood 112: 3807-3817, 2008.
9. Awan FT, Kay NE, Davies ME, et al.: Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphomide, and rituximab. Blood 133: 535-537, 2009.
10. Hussain SR, Cheney CM, Johnson AJ, et al.: Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: downregulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity. Clin Cancer Res 13: 144-150, 2007.
11. Chen R, Keating MJ, Gandhi V and Plunkett W: Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood 106: 2513-2519, 2005. (Pubitemid 41510827)
12. Willis SN, Chen L, Dewson G, et al.: Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 19: 1294-1305, 2005. (Pubitemid 41003019)
13. Smit L, Hallaert DYH, Spijker R, et al.: Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. Blood 109: 1660-1668, 2007. (Pubitemid 46242110)
14. Inoue S, Riley J Gant TW, Dyer MJS and Cohen GM: Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa. Leukemia 21: 1773-1782, 2007. (Pubitemid 47086766)
15. Nencioni A, Hua F, Dillon CP, et al.: Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis. Blood 105: 3255-3262, 2005.
16. Inoue S, Walewska R, Dyer MJS and Cohen GM: Downregulation of Mcl-1 potentiates HDACi-mediated apoptosis in leukemic cells. Leukemia 22: 819-825, 2008. (Pubitemid 351552631)
17. Faderl S, Rai K, Gribben J, et al.: Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia. Cancer 107: 916-924, 2006. (Pubitemid 44291139)
18. Byrd JC, Marcucci G, Parthum MR, et al.: A phase I and pharmacodynamic study of depsipeptide (FK220) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 105: 959-967, 2005. (Pubitemid 40170861)
19. Quiney C, Billard C, Faussat AM, et al.: Pro-apoptotic properties of hyperforin in leukemic cells from patients with chronic lymphocytic leukemia. Leukemia 20: 491-497, 2006. (Pubitemid 43291749)
20. Quiney C, Billard C, Salanoubat C, Fourneron JD and Kolb JP: Hyperforin, a new lead compound against the progression of cancer and leukemia? Leukemia 20: 1519-1525, 2006. (Pubitemid 44264093)
21. Quiney C, Billard C, Mirshahi P, Fourneron JD and Kolb JP: Hyperforin inhibits MMP-9 secretion by B-CLL cells and microtubule formation by endothelial cells. Leukemia 20: 583-589, 2006.
22. Quiney C, Billard C, Faussat AM, Salanoubat C and Kolb JP: Hyperforin inhibits P-gp and BCRP activities in chronic lymphocytic leukaemia cells and myeloid cells. Leuk Lymphoma 48: 1587-1599, 2007. (Pubitemid 47272809)
23. Zaher M, Akrout I, Mirshahi M, Kolb JP and Billard C: Noxa upregulation is associated with apoptosis of chronic lymphocytic leukemia cells induced by hyperforin but not flavopiridol. Leukemia 23: 594-596, 2009.
24. Hallek M, Cheson BD, Catovsky D, et al.: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111: 5446-5456, 2008.
25. kip1 in malignant cells from B-cell chronic lymphocytic leukemia. Leukemia 17: 2345-2443, 2003.
26. Stacchini A, Aragno M, Vallario A, et al.: MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation. Leuk Res 23: 127-136, 1999. (Pubitemid 29067556)
27. Fourneron JD and Naït-Si Y: Effect of eluent pH on HPLC/UV analysis of hyperforin. Phytochem Anal 17: 71-77, 2006.
28. Moravec RA, O'Brien MA, Daily WJ, Scurria MA, Bernad L and Riss TL: Cell-based bioluminescent assays for all three proteasome activities in a homogeneous format. Anal Biochem 387: 294-302, 2009.
29. Kern C, Cornuel J, Billard C, et al.: Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 103: 679-688, 2004. (Pubitemid 38145555)
30. Nencioni A, Grünebach F, Patrone F, Ballestrero A and Brossart P: Proteasome inhibitors: antitumor effects and beyond. Leukemia 21: 30-36, 2007. (Pubitemid 44921831)
31. Chen D, Daniel KG, Chen MS, Kuhn DJ, Landis-Piwowar KR and Ping Dou Q: Dietary flavonoid as proteasome inhibitors and apoptosis inducers in human leukemia cells. Biochem Pharmacol 69: 1421-1432, 2005. (Pubitemid 40602442)
32. Dai Y, De Sano J, Tang W, et al.: Natural proteasome inhibitor celastrol suppresses androgen-independent prostate cancer progression by modulating apoptotic proteins and NF-kappaB. PloS One 5: e14153, 2010.
33. Baou M, Kohlhaas SL, Butterworth M, et al.: Role of Noxa and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells. Haematologica 95: 1510-1518, 2010.
34. Qin JZ, Ziffra J, Stennett L, et al.: Proteasome inhibitors trigger Noxa-mediated apoptosis in melanoma and myeloma cells. Cancer Res 65: 6282-6293, 2005. (Pubitemid 40994414)
35. Li R, Zang Y, Li C, Patel NS, Grandis JR and Johnson DE: ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway. Mol Pharmacol 75: 1231-1239, 2009.
36. Ploner C, Kofler R and Villunger A: Noxa: at the tip of the balance between life and death. Oncogene 27: S84-S92, 2009.
37. Mackus WJM, Kater AP, Grummels A, et al.: Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation. Leukemia 19: 427-434, 2005. (Pubitemid 40403321)
38. Iglesias-Serret D, De Frias M, Sanidrian AF, et al.: Regulation of the proapoptotic BH3-only protein BIM by glucocorticoids, survival signals and proteasome in chronic lymphocytic leukemia cells. Leukemia 21: 281-287, 2007. (Pubitemid 46158121)
39. Ghiotto F, Fais F, Tenca C, et al.: Apoptosis of B-cell chronic lymphocytic leukemia cells induced by a novel BH3 peptidomimetic. Cancer Biol Ther 8: 263-271, 2009.
40. Vogler M, Butterworth M, Majid A, et al.: Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood 113: 4403-441, 2009.
41. Merle-Béral H, Barbier S, Roué G, Bras M, Sarfati M and Susin SA: Caspase-independent type III PCD: a new means to modulate cell death in chronic lymphocytic leukemia. Leukemia 23: 974-977, 2009.
42. Gey C, Kyrylenko S, Hennig L, Nguyen LHD, Büttner A, Pham HD and Giannis A: Phloroglucinol derivatives guttiferone G, aristoforin, and hyperforin: inhibitors of human sirtuins SIRT1 and SIRT2. Angew Chem Int Ed 46: 5219-5222, 2007. (Pubitemid 47051294)
43. Rothley M, Schmid A, Thiele W, et al.: Hyperforin and aristoforin inhibit lymphatic endothelial cell proliferation in vitro and in vivo and suppress tumor-induced lymphangiogenesis in vivo. Int J Cancer 125: 34-42, 2009.
44. O'Brien SM, Claxton DF, Crump M, et al.: Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 113: 299-305, 2009.
45. Balakrishnan K, Burger JA, Wierda WG and Gandhi V: AT-101 induces apoptosis in CLL B cells and overcomes stromal cellmediated Mcl-1 induction and drug resistance. Blood 113: 149-153, 2009.